Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Ocugen's Capital Expenditure for the
three
months ended in Dec. 2023 was $-2.72 Mil. Its Revenue for the
three
months ended in Dec. 2023 was $6.04 Mil.
Hence, Ocugen's Capex-to-Revenue for the
three
months ended in Dec. 2023 was 0.45.
Ocugen Capex-to-Revenue Historical Data
The historical data trend for Ocugen's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ocugen's Capex-to-Revenue
For the Biotechnology subindustry, Ocugen's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocugen's Capex-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocugen's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ocugen's Capex-to-Revenue falls into.
Ocugen Capex-to-Revenue Calculation
Ocugen's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocugen (NAS:OCGN) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Ocugen Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ocugen's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCGN has been successfully added to your 